Literature DB >> 543406

The effect of prostaglandin E1 on acetylcholine release from the cat brain.

L G Hársing, P Illés, S Fürst, E S Vizi, J Knoll.   

Abstract

Cerebral ventricular perfusion with prostaglandin E1 (PGE1, 1.4 X 10(-8) M) reduced the release of acetylcholine (ACh) into the ventriculo-cisternal perfusate of the unanaesthetized cat's brain. The samples of effluent were assayed on the isolated guinea-pig ileum. Neither a halving (1.07 X 10(-3) M) nor a threefold rise (6.45 X 10(-3) M) in the calcium concentration of the perfusate had any effect on the spontaneous release of the cholinergic transmitter. The action of PGE1 was counteracted by decreasing and potentiated by increasing the extracellular calcium concentration. Polyphloretin phosphate (PPP, 10(-4) g/ml) in itself did not significantly affect the ACh outflow. Preperfusion however, with this drug readily antagonized the depressant effect of PGE1. Ouabain (2.0 X 10(-5) M) added to the perfusion fluid increased the ACh output from the cat brain, and PGE1 prevented this effect of ouabain. A single intraventricular injection of 6-hydroxydopamine (1 mg) counteracted the inhibitory effect of PGE1 on spontaneous ACh release. A perfusion with the potent PG synthesis inhibitor suprofen (3.8 X 10(-7) M) did not influence change the mean output of the transmitter. Our data indicate that PGE1 reduces ACh release in the CNS via a pre- or postsynaptic modification of monoaminergic neurotransmission.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 543406

Source DB:  PubMed          Journal:  Acta Physiol Acad Sci Hung        ISSN: 0001-6756


  2 in total

1.  Role of putative neurotransmitters in the central gastric antisecretory effect of prostaglandin E2 in rats.

Authors:  J Puurunen
Journal:  Br J Pharmacol       Date:  1985-05       Impact factor: 8.739

2.  Prostaglandins of the E series inhibit monoamine release via EP3 receptors: proof with the competitive EP3 receptor antagonist L-826,266.

Authors:  J Günther; K Schulte; D Wenzel; B Malinowska; E Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-10       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.